Therapeutic utility of plasminogen activator inhibitor-1 to cont

Details Therapeutic utility of plasminogen activator inhibitor-1 to cont Therapeutic utility of plasminogen activator inhibitor-1 to cont

1992-01-10

1993-10-19

Schain, Howard E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 21, 530300, 530350, A61K 3764

Patent

active

052545369

ABSTRACT:
Pharmaceutical compositions for controlling, by topical administration, localized bleeding in a patient, the composition comprising active PAI-1 protein in an amount effective to control the localized bleeding when topically administered, and a vehicle suitable for the topical administration, as well as methods and kits employing the same, are disclosed.

REFERENCES:
Stump et al., Semin. Thromb. Hemos., vol. 16, No. 3, pp. 260-273 (1990).
Lijnen et al., Fibrinolysis, vol. 3, pp. 67-77 (1989).
Van Mourik et al., J. Biol. Chem., vol. 259, pp. 14914-14921 (1984).
Colucci et al., J. Clin. Invest., vol. 75, pp. 818-824 (1985).
Almer et al., Thromb. Research, vol. 47, pp. 335-339 (1987).
Hamsten et al., New England J. of Medicine, vol. 313, pp. 1557-1563 (1985).
Wiman et al., J. Lab. Clin. Med., vol. 105, pp. 265-270 (1985).
Colucci et al., J. Clin. Invest., vol. 78, pp. 138-144 (1986).
Ehrlich et al., J. Biol. Chem., vol. 265, pp. 13029-13035 (1990).
Reilly et al., J. Biol. Chem., vol. 265, No. 16, pp. 9570-9574 (1990).
Racanelli et al., Fibr., vol. 4, Suppl. 3, p. 43 (1990).
Vaughan et al., J. Clin. Invest., vol. 84, pp. 586-591 (1989).
Schwartz, Principles of Surgery, Ch. 3, 5th ed., New York, McGraw-Hill (1984).
Stajcic et al., Int. J. Oral Surg., vol. 14, No. 4, pp. 339-345 (1985).
Allingham et al., Arch. Ophthalmol., vol. 105, No. 10, pp. 1421-1423 (1987).
Verstraete, Drugs, vol. 29, pp. 236-261 (1985).
Maurice, Int. Ophthalmol. Clin., vol. 20, pp. 21-30 (1980).
Cramer et al., Blood, vol. 77, No. 4, pp. 694-699 (1991).
Coleman et al., J. Biol. Chem., vol. 257, pp. 4260-4264 (1982).
Kruithof et al., Thromb. Haemostasis, vol. 59, pp. 7-12 (1988).
Booth et al., Eur. J. Biochem., vol. 165, pp. 595-600 (1987).
Andreasen et al., J. Biol. Chem., vol. 261, pp. 7644-7651 (1986).
Zeheb et al., Thromb. Haemostasis, vol. 58, pp. 1017-1023 (1987).
Hekman et al., J. Biol. Chem., vol. 260, pp. 11581-11587 (1985).
Lambers et al., J. Biol. Chem., vol. 262, pp. 17492-17496 (1987).
Ginsburg et al., J. Clin. Invest., vol. 78, pp. 1673-1680 (1986).
Ny et al., Proc. Natl. Acad. Sci. U.S.A., vol. 83, pp. 6776-6781 (1986).
Pannekoek et al., EMBO J., vol. 5, pp. 2539-2544 (1986).
Wun et al., FEBS Lett., vol. 210, pp. 11-16 (1987).
Alessi et al., Eur. J. Biochem., vol. 175, pp. 531-540 (1988).
Andreasen et al., FEBS Lett., vol. 209, pp. 213-218 (1986).
Sisk et al., Gene (Amst.), vol. 96, pp. 305-309 (1990).
Remington's Pharmaecutical Sciences, Gennaro, A. R., ed., Mack Publishing Co., Easton, Pa. (1985).
The United States Pharmacopeia--The National Formulary, 22nd Revision, Mack Printing Company, Easton Pa. (1990).
McFarlane, Plas. and Reconstr. Surg., vol. 35, No. 2, pp. 177-182 (1965).
Coleman, J. Biol. Chem., vol. 261, pp. 4352-4357 (1986).
Jasani et al., Lancet, vol. 2, pp. 332-333 (1977).
Awe et al., Surgical Bleeding, Ulin, A. W. and Gollub, S. S., eds., pp. 427-431, New York, McGraw Hill (1966).
Seegers et al., Proc. Soc. Exp. Biol. Med., vol. 56, pp. 72-77 (1944).

Affiliated with

Also associated with

Rating

Therapeutic utility of plasminogen activator inhibitor-1 to cont does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic utility of plasminogen activator inhibitor-1 to cont, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic utility of plasminogen activator inhibitor-1 to cont will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1351732